Protection of mice against Human respiratory syncytial virus by wild-type and aglycosyl mouse–human chimaeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein
- 1 May 2006
- journal article
- Published by Microbiology Society in Journal of General Virology
- Vol. 87 (5) , 1267-1273
- https://doi.org/10.1099/vir.0.81660-0
Abstract
Monoclonal antibodies (mAbs) to conserved epitopes on the G glycoprotein of human respiratory syncytial virus (HRSV) subgroup A fail to neutralize the virus in cell culture in the absence of complement, but are protective in rodent models of infection. They may have potential as prophylactic agents in human infants. In order to investigate the role of Fc-dependent pathways in protection by one such antibody, 1C2, the VHand VLgenes were isolated by RT-PCR and assembled with humanκlight-chain and humanγ1 heavy-chain constant-region genes to form two mouse–human chimaeras, which were expressed in NS0 cells. One of the chimaeras carried a wild-typeγ1 chain, whilst the other had an aglycosyl mutation in the CH2 domain rendering the antibody defective in complement activation and FcγR binding. Whilst both chimaeric antibodies exhibited similar avidity for HRSV in ELISA, only the fully glycosylated wild type was capable of neutralizing the virus in the presence of complement. In mice passively immunized with either murine or wild-typeγ1 chimaeric antibody, no virus could be recovered from the lungs 4 days after intranasal inoculation of HRSV. In mice immunized with the aglycosylγ1 chimaera, however, virus was present in the lungs following challenge, although virus titres were significantly reduced compared with controls (P<0·005). These results indicate that the protective effect of this antibody is mediated by both Fc-dependent and Fc-independent pathways.Keywords
This publication has 37 references indexed in Scilit:
- Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibodyThe Journal of Pediatrics, 2003
- The Fusion Glycoprotein of Human Respiratory Syncytial Virus Facilitates Virus Attachment and Infectivity via an Interaction with Cellular Heparan SulfateJournal of Virology, 2000
- Immunization with a peptide derived from the G glycoprotein of bovine respiratory syncytial virus (BRSV) reduces the incidence of BRSV-associated pneumonia in the natural hostVaccine, 1997
- Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2Vaccine, 1996
- Solution Structure of the Immunodominant Region of Protein G of Bovine Respiratory Syncytial Virus,Biochemistry, 1996
- Evaluation of subgroup‐specific peptides of the G protein of respiratory syncytial virus for characterization of the immune responseJournal of Medical Virology, 1995
- In vivo production of tumour necrosis factor-α and interleukin-6 in BALB/c mice inoculated intranasally with a high dose of respiratory syncytial virusJournal of Medical Virology, 1994
- The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive propertiesEuropean Journal of Immunology, 1993
- The binding site for C1q on IgGNature, 1988
- Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody levelThe Journal of Pediatrics, 1981